enasidenib
Sign in to saveAlso known as AG-221, CC-90007, 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol
Enasidenib, sold under the brand name Idhifa, is an anti-cancer medication used to treat relapsed or refractory acute myeloid leukemia. It is an inhibitor of isocitrate dehydrogenase 2 (IDH2).
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 473.139878
- Has use
- medication
Show 5 more facts
- chemical formula
- C₁₉H₁₇F₆N₇O
- canonical SMILES
- CC(C)(CNC1=NC(=NC(=N1)NC2=CC(=NC=C2)C(F)(F)F)C3=NC(=CC=C3)C(F)(F)F)O
- NCI Thesaurus ID
- C111573
- medical condition treated
- acute myeloid leukemia
- Commons category
- Enasidenib
via Wikidata · CC0
~3 min read
Encyclopedic overview
7 sectionsContents
- Medical use
- Adverse effects
- History
- Society and culture
- Legal status
- References
- External links
Enasidenib, sold under the brand name Idhifa, is an anti-cancer medication used to treat relapsed or refractory acute myeloid leukemia. It is an inhibitor of isocitrate dehydrogenase 2 (IDH2).
Common side effects of enasidenib include nausea, vomiting, diarrhea, increased levels of bilirubin (substance found in bile), and decreased appetite. Women who are pregnant or breastfeeding should not take enasidenib because it may cause harm to a developing fetus or a newborn baby.
Excerpted from Wikipedia’s “enasidenib” article, available under the CC BY-SA 4.0 licence.